Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss

M Sodhi, R Rezaeianzadeh, A Kezouh, M Etminan - Jama, 2023 - jamanetwork.com
Methods| We used a random sample of 16 million patients (2006-2020) from the PharMetrics
Plus for Academics database (IQVIA), a large health claims database that captures 93% of …
被引用次数：94 相关文章

[引用][C] Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

M Sodhi, R Rezaeianzadeh, A Kezouh… - JAMA, 2023 - pubmed.ncbi.nlm.nih.gov
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor
Agonists for Weight Loss Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like …

[引用][C] Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.

M Sodhi, R Rezaeianzadeh, A Kezouh, M Etminan - JAMA, 2023 - europepmc.org
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor
Agonists for Weight Loss. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.

M Sodhi, R Rezaeianzadeh… - JAMA: Journal of the …, 2023 - search.ebscohost.com
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor
Agonists for Weight Loss Page 1 Published Online: October 20, 2023. doi:10.1001/jama.2023.17244 …
[HTML] nih.gov

[HTML][HTML] Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

M Sodhi, R Rezaeianzadeh, A Kezouh, M Etminan - JAMA, 2023 - ncbi.nlm.nih.gov
Methods We used a random sample of 16 million patients (2006-2020) from the PharMetrics
Plus database (IQVIA), a large health claims database that captures 93% of all outpatient …